SCHEMBL16619140

SCHEMBL16619140

O=C(O)NCc1ccnnc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.50
CYP1A2 P05177 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
CYP2D6 P10635 1/20 0.46
TSHR P16473 1/20 0.46
LOXL2 Q9Y4K0 1/20 0.45
HCAR2 Q8TDS4 1/20 0.44
CHRM4 P08173 1/20 0.43
GAA P10253 3/20 0.42
RECQL P46063 1/20 0.42
MAPT P10636 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP3A4 P08684 1/20 0.41
HTT P42858 2/20 0.40
USP2 O75604 1/20 0.40
VNN1 O95497 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
LMNA P02545 1/20 0.39
HPGD P15428 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16891678 0.83 KMT2A (0.49) HSD17B10LOXL2CHRM4RECQLMAPT
SCHEMBL23022738 0.83 HSD17B10 (0.45) HSD17B10CYP1A2CYP2C9CYP2C19LOXL2
SCHEMBL30421298 0.83 KMT2A (0.49) HSD17B10LOXL2CHRM4RECQLMAPT
SCHEMBL21246182 0.83 RECQL (0.62) HSD17B10CYP2C9CYP2C19LOXL2HCAR2
SCHEMBL1416389 0.81 MMP13 (0.57) GAAMAPTALDH1A1CYP3A4HTT
SCHEMBL19151160 0.80 MAPT (0.43) HSD17B10CYP1A2CYP2C9CYP2C19LOXL2
SCHEMBL19387965 0.79 HDAC6 (0.50) HSD17B10LOXL2CHRM4MAPTALDH1A1
SCHEMBL20233523 0.79 ERCC1 (0.51) HSD17B10CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL334662 0.78 GAA (0.64) HSD17B10CYP1A2CYP2C9CYP2C19CYP2D6
SCHEMBL30437853 0.78 GAA (0.64) HSD17B10CYP1A2CYP2C9CYP2C19CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052099-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2019-08-21 EP disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
EP-3052099-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS Merck Sharp & Dohme Corp. (US) 2016-08-10 EP disclosed
WO-2015050798-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 HSD17B10 2611/4885CYP1A2 583/4885CYP2C9 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.